News
AKBA
1.325
-3.28%
-0.045
Weekly Report: what happened at AKBA last week (0415-0419)?
Weekly Report · 3d ago
AKEBIA THERAPEUTICS INC: ON APRIL 15, COMPANY AND STA ENTERED INTO AMENDMENT #2 TO SUPPLY AGREEMENT
Reuters · 04/16 11:35
Weekly Report: what happened at AKBA last week (0408-0412)?
Weekly Report · 04/15 10:36
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
IN8bio stock increased by 47.7% to $1.61 during Wednesday's pre-market session. Jaguar Health (NASDAQ:JAGX) shares rose 25.0% during the session. China SXT Pharmaceuticals shares moved upwards by 24.85%. Losers in the market were BioSig Technologies and Kineta.
Benzinga · 04/10 12:09
Weekly Report: what happened at AKBA last week (0401-0405)?
Weekly Report · 04/08 10:39
Buy Vafseo's Approval: A New Chapter For Akebia Therapeutics In Anemia Management
Akebia Therapeutics, Inc.'s drug Vadadustat, known as Vafseo, received FDA approval for the treatment of anemia in adults on dialysis in March 2024. The company's other FDA-approved drug, Auryxia, will face generic competition in March 2025. Akebia is a biopharmaceutical company specializing in anemia management due to chronic kidney disease. Its drug, VafSEo, is expected to become the company's main revenue driver. I lean towards a cautious "Buy" for Akebia.
Seeking Alpha · 04/04 21:56
Akebia's Vafseo Faces Grim Market Outlook (Rating Downgrade)
Akebia's Vafseo, a HIF-PH inhibitor for DD-CKD anemia, faces skepticism despite FDA approval due to safety concerns. The drug was approved in March for adults with dialysis-dependent chronic kidney disease. GSK's Jesduvroq was approved for the same indication last year. Akebia's financials show modest net income and a shrinking cash reserve.
Seeking Alpha · 04/02 10:16
Weekly Report: what happened at AKBA last week (0325-0329)?
Weekly Report · 04/01 10:38
AKEBIA THERAPEUTICS INC <AKBA.O>: BTIG RAISES TARGET PRICE TO $5 FROM $4
Reuters · 04/01 03:51
12 Health Care Stocks Moving In Friday's Intraday Session
Avalo Therapeutics (NASDAQ:AVTX) shares increased by 364.8% to $22.08 during Friday's regular session. The company's market cap stands at $510.4 million. Nexalin Technology shares moved upwards by 83.33% and Biodexa Pharmaceuticals stock increased by 81.6%. Losers include Tonix Pharmaceuticals and Kodiak Sciences.
Benzinga · 03/29 16:30
Akebia Therapeutics Price Target Raised to $6.00/Share From $5.00 by HC Wainwright & Co.
Dow Jones · 03/28 16:29
Akebia Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/28 16:29
HC Wainwright & Co. Maintains Buy on Akebia Therapeutics, Raises Price Target to $6
Benzinga · 03/28 16:20
FDA Approves For Akebia Therapeutics' Vafseo For Kidney Disease Associated Anemia
FDA approves Akebia's Vafseo tablets for anemia due to chronic kidney disease in adults receiving dialysis. The drug is now approved in 37 countries. Approximately 500,000 adult patients in the U.S. On dialysis suffer from anemia.
Benzinga · 03/28 13:50
BUZZ-U.S. STOCKS ON THE MOVE-Gold miners, B Riley, Xilio Therapeutics
Wall Street's main stock indexes set to open flat on Thursday in thin trading ahead of Easter break. Dow e-minis up 0.11%, S&P 500 and Nasdaq 100 down 0.02%. Top three NYSE percentage gainers premarket: Cazoo Group, Xilio Therapeutics. Gold miners rise on U.S. Interest rate cut bets. B Riley Financial up 6.7% in premarket.
Reuters · 03/28 13:18
Why RH Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
RH posted weaker-than-expected results for its fourth quarter, but issued upbeat forecast. The company's shares jumped 9.4% to $324.99 in pre-market trading. Avalo Therapeutics, Inc. Gained 256.6% on Wednesday.
Benzinga · 03/28 12:21
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Avalo Therapeutics (NASDAQ:AVTX) shares rose 328.2% to $20.34 during Thursday's pre-market session. Xilio Therapeutic (XLO) stock moved upwards by 223.94% during the session. Akanda (AKAN) shares increased by 27.1% and INVO Bioscience (INVO) stock increased by 16.36%. NuCana (NCNA) stock declined by 19.8% in the pre- market.
Benzinga · 03/28 12:06
BUZZ-U.S. STOCKS ON THE MOVE-Crypto stocks, Akebia Therapeutics, Sprinklr
U.S. Stock index futures were lackluster on Thursday. Investors await more data to gauge the state of the economy and the Fed's policy path. The top three NYSE percentage gainers premarket were Akebia Therapeutics, Sprinklr. Crypto stocks up as bitcoin, ether prices recover from two-day slide.
Reuters · 03/28 11:54
Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD
NASDAQ · 03/28 11:06
Analysts Offer Insights on Healthcare Companies: Integer Holdings (ITGR), Akebia Therapeutics (AKBA) and Moderna (MRNA)
TipRanks · 03/28 11:00
More
Webull provides a variety of real-time AKBA stock news. You can receive the latest news about Akebia Therapeut through multiple platforms. This information may help you make smarter investment decisions.
About AKBA
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company is focused on developing and commercializing therapeutics. The Company’s portfolio and hypoxia-inducible factor (HIF)-based pipeline includes Auryxia (ferric citrate), Vafseo (vadadustat), AKB-9090 and AKB-10108. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo (vadadustat) is a HIF prolyl hydroxylase (HIF-PH), inhibitor, approved in 36 countries as a treatment for anemia due to chronic kidney disease (CKD). It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.